Effects of Dipeptidyl Peptidase-4 Inhibition With Saxagliptin on Fasting and Postprandial Triglyceride Concentrations
Phase of Trial: Phase IV
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Saxagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 14 Oct 2015 Planned End Date changed from 1 Dec 2013 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
- 14 Oct 2015 Planned primary completion date changed from 1 Dec 2013 to 1 Nov 2016 as reported by clinicalTrials.gov record.
- 10 Feb 2012 New trial record